Allecra Therapeutics Successfully Enters Next Development Phase Ready to start pivotal Phase III clinical trial Allecra secures Series C €14M financing from existing shareholdersDr. Klaus Wilgenbus appointed as CEO and Dr. Mathias Knecht as second Managing...

Allecra Therapeutics to Present Data at 28th European Congress of Clinical Microbiology and Infectious Diseases LÖRRACH, Germany and SAINT LOUIS, France, April 17, 2018 (GLOBE NEWSWIRE) -- Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel...

Allecra Therapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 LÖRRACH, Germany and SAINT LOUIS, France, April 03, 2018 (GLOBE NEWSWIRE) -- Allecra Therapeutics (Private), today announced it will be featured as a presenting company at the H.C. Wainwright...